MedTech Dive June 20, 2024
With the clearance, Globus could gain share in the roughly $15 billion market for reconstructive orthopedic surgery, RBC Capital Markets analyst Shagun Singh said.
Dive Brief:
- Globus Medical received 510(k) clearance from the Food and Drug Administration for its ExcelsiusFlex orthopedics robot, according to a posting from the agency.
- CEO Dan Scavilla said in a May investor call that Globus had filed a submission for a reconstruction robot with the FDA and expected clearance late in the third quarter. A June 14 filing describes ExcelsiusFlex as a device that provides stereotaxic guidance during orthopedic joint or spine surgeries.
- RBC Capital Markets analyst Shagun Singh, who first pointed out the FDA’s notification in an emailed research note, said that Globus...
Today's Sponsors
Today's Sponsor